Tectonic Therapeutic, Inc. Total Liabilities
Tectonic Therapeutic, Inc. total liabilities. Based on the latest financial reports, Tectonic Therapeutic, Inc. (TECX) has total liabilities worth $13.19 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check TECX cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Tectonic Therapeutic, Inc. (2016–2025)
Total liabilities of Tectonic Therapeutic, Inc. from 2016 to 2025. This chart illustrates how Tectonic Therapeutic, Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Tectonic Therapeutic, Inc. Competitors by Total Liabilities
The table below lists competitors of Tectonic Therapeutic, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Luoyang Glass
SHG:600876
|
China | CN¥10.33 Billion |
|
Jiangsu Huifeng Agrochemical Co Ltd
SHE:002496
|
China | CN¥987.73 Million |
|
Huchems
KO:069260
|
Korea | ₩259.89 Billion |
|
USI Corp
TW:1304
|
Taiwan | NT$29.60 Billion |
|
Bafang Yunji Intl Co Ltd
TW:2753
|
Taiwan | NT$4.26 Billion |
|
Shanghai Nar Industrial Co Ltd
SHE:002825
|
China | CN¥1.14 Billion |
|
LF Corp
KO:093050
|
Korea | ₩1.30 Trillion |
|
Yuanbao Inc. American Depositary Shares
NASDAQ:YB
|
USA | $1.71 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Tectonic Therapeutic, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see TECX asset base.
Liquidity & Leverage Metrics
Tectonic Therapeutic, Inc. Total Liabilities Ratios Explained
Tectonic Therapeutic, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 22.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tectonic Therapeutic, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tectonic Therapeutic, Inc. (2016–2025)
The table below shows the annual total liabilities of Tectonic Therapeutic, Inc. from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $9.71 Million | -19.95% |
| 2024-12-31 | $12.13 Million | -90.22% |
| 2023-12-31 | $124.03 Million | +33.57% |
| 2022-12-31 | $92.86 Million | +94.12% |
| 2021-12-31 | $47.84 Million | +183.23% |
| 2020-12-31 | $16.89 Million | +16.47% |
| 2019-12-31 | $14.50 Million | +28.38% |
| 2018-12-31 | $11.29 Million | +208.86% |
| 2017-12-31 | $3.66 Million | +273.54% |
| 2016-12-31 | $979.00K | -- |
About Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RX… Read more